Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Follicular Lymphoma Treatment Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The follicular lymphoma treatment market size has experienced robust growth in recent times. It is projected to increase from $3.28 billion in 2025 to $3.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. The historical growth in this period can be ascribed to progress in monoclonal antibodies, greater recognition of lymphoma, a surge in oncology research, the enlargement of hospital facilities, and the increasing incidence of Non-Hodgkin lymphoma.
The follicular lymphoma treatment market is anticipated to experience substantial growth over the next few years. It is expected to expand to $4.91 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. The projected increase in this period can be attributed to breakthroughs in targeted therapy, the integration of AI into treatment planning, an escalation in stem cell transplant procedures, the expansion of oncology centers in emerging markets, and the development of biosimilars. Prominent trends for the forecast period include personalized treatment protocols, the creation of novel monoclonal antibodies, combination therapy approaches, initiatives for early diagnosis and screening, and the utilization of minimally invasive treatment techniques.
Get A Free Sample Report With In-Depth Market Insights:
Follicular Lymphoma Treatment Market Growth Backed By Core Demand Fundamentals
The increasing incidence of follicular lymphoma is anticipated to drive expansion in the follicular lymphoma treatment market. Follicular lymphoma prevalence denotes the overall count or percentage of individuals in a defined population identified with the condition at a specific moment or across a certain timeframe. This trend stems from an expanding aging demographic, genetic susceptibility, advancements in diagnostic methods, and enhanced awareness and screening efforts. Treating follicular lymphoma assists in diminishing its prevalence by managing the illness across different stages and supporting its treatment and progression control. The escalating occurrence of follicular lymphoma is accelerating the expansion of the follicular lymphoma treatment market. As an illustration, in January 2023, data from the American Cancer Society, a US-based Voluntary organization, indicated that non-Hodgkin lymphoma, which includes indolent follicular lymphoma, stands as the most common cancer in the US, making up approximately 4% of all malignancies. The American Cancer Society forecasts diagnoses of NHL in roughly 80,550 individuals (44,880 men and 35,670 women). This figure encompasses both adults and pediatric cases. Consequently, the growing prevalence of follicular lymphoma is fueling the growth of the follicular lymphoma treatment market.
Follicular Lymphoma Treatment Market Segmentation: How Does The Market Break Down By Category?
The follicular lymphoma treatment market covered in this report is segmented –
1) By Treatment: Monoclonal Antibodies, Targeted Therapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Alkylating Agents
2) By Product Type: Tablets, Capsules, Injectables, Other Product Types
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By End Use: Hospitals, Oncology Centers, Ambulatory Care Centers, Academic Research Institutes, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Rituximab, Obinutuzumab, Ofatumumab
2) By Targeted Therapy: PI3K Inhibitors, BTK Inhibitors, BCL-2 Inhibitors
3) By Chemotherapy: CHOP Regimen, Bendamustine, Fludarabine
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioimmunotherapy
5) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
6) By Alkylating Agents: Cyclophosphamide, Ifosfamide
Follicular Lymphoma Treatment Market Growth Trends Reshaping The Competitive Landscape
Leading companies within the follicular lymphoma treatment market are actively developing advanced solutions like bispecific antibodies to enhance durable remission and lessen the burden of patient treatment. A bispecific antibody is an engineered molecule designed to simultaneously bind two different targets; for example, one arm connects to a tumor antigen on B cells while the other engages T cells, thereby more effectively redirecting the immune system to eradicate cancer cells. Illustratively, in March 2025, Chugai Pharmaceutical, a Japan-based research-driven oncology company, introduced LUNSUMIO, which features a CD20/CD3 bispecific antibody system. LUNSUMIO is approved as an intravenous infusion in 1 mg and 30 mg formulations and is intended for patients with relapsed or refractory follicular lymphoma who have previously failed at least two standard therapies. This therapy is structured for fixed-duration treatment, adapting to individual patient response, which can consequently reduce the long-term treatment burden. LUNSUMIO has exhibited high complete response rates and offers the potential for durable remission when administered as a monotherapy.
Follicular Lymphoma Treatment Market Competitive Overview And Top Companies
Major companies operating in the follicular lymphoma treatment market are AbbVie Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson and Johnson Services Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Boehringer Ingelheim GmbH, CTI BioPharma Corp., Spectrum Pharmaceuticals Inc., Seattle Genetics Inc., Daiichi Sankyo Company Ltd., Pfizer Inc., Incyte Corporation, MorphoSys AG, Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Seagen Inc., Takeda Pharmaceutical Company, Nordic Nanovector ASA, ADC Therapeutics SA, MEI Pharma Inc., BeiGene Inc., TG Therapeutics Inc., Amgen Inc.
View The Full Follicular Lymphoma Treatment Market Report:
Follicular Lymphoma Treatment Market Geographic Spread And Regional Opportunities
North America was the largest region in the follicular lymphoma treatment market in 2025. The regions covered in the follicular lymphoma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
